INTRODUCTION

The use of medications in pregnancy and lactation presents a challenge to all health care providers. This is especially true with the long-standing pregnancy risk categories A, B, C, D, and X (Table 1), which make risk–benefit ratio assessment difficult. Numerous medications have been used safely and effectively in pregnancy with minimal risk to the fetus and mother, although the decision to use them is not without apprehension. The availability of more detailed information related to the safety and efficacy of medications in pregnancy and lactation may assist providers and patients in making more evidence-based decisions.1

To address the need for updated risk categories, the Food and Drug Administration (FDA) published a final rule entitled Content and Format of Labeling for Human Prescription Drug and Biological Products: Requirements for Pregnancy and Lactation Labeling, which is also known simply as the “Pregnancy and Lactation Labeling Rule” (PLLRR), in December 2014.2,3 Along with the PLLRR, the FDA issued a draft document entitled Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products—Content and Format to serve as a guidance to industry in preparing PLLRR-compliant drug applications.2 The PLLRR represents a significant departure from the previously established pregnancy categories, initially implemented in the FDA’s 1979 Labeling for Prescription Drugs Used in Man regulations.2,5 These regulations required the assignment of a pregnancy letter category (A, B, C, D, or X) to medications (Table 1).4 Under the PLLRR, these categories are being phased out, which will be discussed later in this article.

DEVELOPING THE PLLRR

During the development of the PLLRR, the FDA received input from public hearings, focus groups, and advisory committees. Input from these sessions and groups included concerns that the existing pregnancy categories may be misinterpreted or misused and that pregnancy drug labeling lacked clarity. In addition, the groups reported that the categories failed to provide meaningful clinical information about drug exposure during pregnancy and lactation and did not address the potential maternal and fetal consequences of discontinuing needed drug therapy during pregnancy.2 In the new PLLRR, drugs may be placed in the same category but have varying degrees of risk that a single letter category oversimplifies. For example, 60% of all medications assigned a pregnancy category fall into category C. This category includes medications with data supporting adverse effects in animals, as well as medications with no data from animal studies; the older pregnancy category system allows drugs with evidence of risk and those without evidence of risk to be assigned the same category.5 These previous pregnancy categories are defined not by severity or incidence of risk, but rather by the amount and quality of available data.2

The FDA also conducted a mental-models research study in 2009 to understand the treatment decisions of health care professionals prescribing medications to pregnant and lactating women.6 This mental-modeling approach compared the decision-making process of study participants to what was considered an “expert” model. A total of 54 health care providers were involved in this study. The prescribers were asked by telephone to describe factors that influence their decisions when treating pregnant and nursing women with chronic conditions.7 The study found that health care providers relied heavily upon pregnancy categories, more so than on additional information found in the product labeling. In addition, prescribers reported they relied on sources other than the labeling to determine the pregnancy category. The study participants suggested ways to improve drug pregnancy labeling, including simplifying the information presented, centralizing the relevant information, and making the information more clinically relevant.5

WHAT THE PLLRR CHANGES

The PLLRR seeks to address the criticisms of the previous labeling system and reform pregnancy labeling with a number of enhancements, including:

- Developing clearer risks categories
- Providing more evidence-based pregnancy categories
- Simplifying risk categories
- Centralizing and prioritizing counseling information
- Providing decision aids
- Improving clinical decision-making tools
- Addressing the adverse effects of medications to the fetus and mother

Table 1 Pregnancy Categories Prior to New Pregnancy and Lactation Labeling Rule2

<table>
<thead>
<tr>
<th>Category</th>
<th>Risk</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy.</td>
<td>Doxylamine, Folic acid, Levothyroxine</td>
</tr>
<tr>
<td>B</td>
<td>Animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women, or animal reproduction studies have shown adverse effects, but well-controlled studies in pregnant women have shown no adverse effects to the fetus.</td>
<td>Amoxicillin, Loratadine, Ondansetron</td>
</tr>
<tr>
<td>C</td>
<td>Animal reproduction studies have shown an adverse effect on the fetus, or there are no animal reproduction studies and no well-controlled studies in humans.</td>
<td>Fluconazole, Metoprolol, Sertraline</td>
</tr>
<tr>
<td>D</td>
<td>Positive evidence of fetal risk, but benefits may outweigh risks.</td>
<td>Lisinopril, Lithium, Phenytioin</td>
</tr>
<tr>
<td>X</td>
<td>Positive evidence of fetal risk, and risks clearly outweigh any possible benefit.</td>
<td>Methotrexate, Simvastatin, Warfarin</td>
</tr>
</tbody>
</table>

Disclosures: The authors report no commercial or financial interests in regard to this article.

Dr. Pernia is a Pharmacy Practice Resident at Jackson Madison County General Hospital in Jackson, Tennessee. Dr. DeMaagd is the Associate Dean of Academic Administration and a Professor of Pharmacy Practice at the Union University School of Pharmacy in Jackson, Tennessee.
of changes to all prescribing information. The PLLR will remove the pregnancy letter categories, change and combine sections pertaining to pregnancy and lactation, and add one new section (Table 2).

The previous sections “8.1 Pregnancy” and “8.2 Labor and Delivery” are now combined to form one section, “8.1 Pregnancy.” This section will include the following subsections: “Pregnancy Exposure Registry,” “Risk Summary,” “Clinical Considerations,” and “Data.” The “Pregnancy Exposure Registry” subsection is required only if such a registry exists for the product and should include information about how to enroll in the registry. The “Risk Summary” subsection should be presented as a narrative and summarize any human, animal, and pharmacological risk data available. It should also include background information regarding the risk of major birth defects and miscarriage in the U.S. general population. The “Clinical Considerations” subsection details disease-associated maternal and fetal risk, relevant dose adjustments, maternal and fetal adverse reactions, and labor and delivery information. The “Data” subsection describes the information used for the “Risk Summary” and “Clinical Considerations” subsections.

The previous section “8.3 Nursing Mothers” now becomes “8.2 Lactation.” Similar to the pregnancy section above, “8.2 Lactation” also contains the subheadings “Risk Summary,” “Clinical Considerations,” and “Data.” The “Risk Summary” describes the presence of the drug in human milk and the effects on milk production and the breastfed child, and contains a statement on the risk–benefit ratio related to use. The “Clinical Considerations” section will include information on minimizing exposure and monitoring for adverse reactions.

The new section incorporated into the PLLR is “8.3 Females and Males of Reproductive Potential.” This section should be utilized in the following situations: 1) if there are recommendations or requirements for pregnancy testing and/or contraception before, during, or after drug therapy, and 2) if there are human and/or animal data suggesting drug-associated effects on fertility and/or preimplantation loss effects. Subheadings in this section include “Pregnancy Testing,” “Contraception,” and “Infertility.”

Finally, the PLLR requires manufacturers to update all labels as new information or data become available.

**IMPLEMENTATION OF THE PLLR**

The PLLR became effective on June 30, 2015, and implementation of this rule will occur in several stages over three to five years from that date. Compliance will be determined by drug application and approval dates (Table 3).

The new rule has several potential limitations. Older medications and over-the-counter products approved prior to June 30, 2001, will have neither a pregnancy category nor a narrative summary readily available to providers. The requirement of close collaboration between the FDA and manufacturers to ensure timely updates also may be problematic. In addition, consumers need to cooperate with the pregnancy registry process and share their health information in order to accumulate a meaningful quantity of data.

**LABELING SAMPLES**

Since the effective date of the PLLR, a total of 48 new novel drugs have been approved by the FDA. Only three of these (insulin degludec injection [Tresiba, Novo Nordisk], brivaracetam [Briviact, UCB, Inc.], and obiltoxaximab [Anthim, Elusys Therapeutics, Inc.]) have not yet conformed to the new rule. Elbasvir/grazoprevir (Zepatier, Merck), approved on January 28, 2016, is a good example of compliance with the PLLR. Its section “8.1 Pregnancy” provides a narrative risk summary and detailed animal data, a background risk statement, and the estimated background risk for major birth defects and miscarriage. Section “8.2 Lactation” similarly summarizes risk and provides available animal data. Because there are no human pregnancy or lactation data for elbasvir/grazoprevir, only the animal data are summarized. Finally, per labeling guidelines, no pregnancy category is provided.

If the previous pregnancy category guidelines were to be applied to elbasvir/grazoprevir, a category of “B” may have been appropriate. However, this category would be overly simplistic and would not detail the animal data available for this agent. Therefore, in this case, a narrative as required for PLLR compliance presents useful information rather than a broad category or recommendation.

Trabectedin (Vondelis, Janssen Biotech), approved on October 23, 2015, also provides labeling that conforms to the PLLR and includes the new section “8.3 Females and Males of Reproductive Potential.” The “Contraception” subheading provides specific contraception guidelines for women and men, while the “Infertility” subheading informs prescribers and

### Table 2: Comparison of Pregnancy and Lactation Labeling Rules: 1979 versus 2015

<table>
<thead>
<tr>
<th>Rule in Phase-Out</th>
<th>New PLLR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 8.1 Pregnancy</td>
<td>Combined to form one section: 8.1 Pregnancy</td>
</tr>
<tr>
<td>Section 8.2 Labor and Delivery</td>
<td>- Risk Summary</td>
</tr>
<tr>
<td>Section 8.3 Nursing Mothers</td>
<td>Becomes Section 8.2 Lactation</td>
</tr>
<tr>
<td>Requirement to update the label as information becomes outdated</td>
<td>Requirement to update the label as information becomes outdated</td>
</tr>
</tbody>
</table>

PLLR = Pregnancy and Lactation Labeling Rule.

* Only included when there are recommendations or requirements for pregnancy testing and/or contraception before, during, or after drug therapy, and/or there are human and/or animal data suggesting drug-associated effects on fertility and/or preimplantation loss effects.

---

patients that Yondelis has the potential to decrease fertility in both genders.16 The labeling information produced under the new rule allows the provider and patent to review and discuss the risks in order to make an informed treatment decision.

CLINICAL IMPACT

Although the PLLR requires a concise, standardized summary of available evidence, the departure from pregnancy categories may prove to be a challenging transition. The FDA received 16 comments regarding the proposed rule that supported the old category system. Those comments stated that the old system was simple and effective and expressed concern that a narrative summary may prove confusing and could lead to inconsistent decision-making.2 The transition to a narrative summary style is not without risk and requires that providers review the available evidence instead of relying on category designations.17 Such evidence review will require more time and may involve some complex decision-making. Risk arises if an incomplete assessment is made or if the evidence is unclear. The lack of a standardized schema may also make it difficult to make blanket formulary decisions because each medication will need a more individualized review.

CONCLUSION

In announcing the final PLLR, Sandra Kweder, MD, Deputy Director of the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research, stated, “Prescribing decisions during pregnancy and lactation are individualized and involve complex maternal, fetal, and infant risk–benefit considerations. The letter category system was overly simplistic and was misinterpreted as a grading system, which gave an oversimplified view of the product risk.”18 The PLLR remedies the perception of pregnancy categories as a grading system by doing away with them altogether. In place of pregnancy categories, the PLLR requires narrative explanations of risk and supporting data.

REFERENCES


